

## **SUMMARY**

The client was able to accelerate and enhance the quality of HTA submissions in selected markets and was provided with analyses to improve future global documents.

## **CLIENT SITUATION**

A biopharmaceutical company wanted to accelerate and enhance the quality of health technology assessment (HTA) submissions in selected markets for an orphan drug in a biomarker-defined patient population.

## PRMA CONSULTING SOLUTION


The PRMA Navigator® was used to rapidly develop auto-populated partial submissions for the reimbursement of a novel treatment in Belgium, France, Italy, Norway, Spain, and Sweden. This included:

**Strategy alignment meetings** to ensure consistent pull-through of global strategy and localize content of HTA submissions.

Tagging the global value dossier (GVD and other global and local supporting documents to map global and local payer domains.

**Auto-population** of partial HTA submissions across the markets.

**GVD gap analyses** to identify payer requirements not met by the GVD and inform future global deliverables.



## **CLIENT VALUE**

- Local affiliates were provided with a partial draft submission, having committed only 2 hours of their time, freeing up time for strategic thinking and local evidence generation.
- Regional leads could be confident of an aligned approach and pull-through of the global HTA strategy.
- Regional team members were provided with GVD gap analyses for each market that could be used to improve future global documents.

Without the PRMA Navigator® it would have been very difficult to keep track of multiple submissions at the same time.

The Navigator made it easy for the European team to align our approach across all markets.

4361





